ongoing

This is a randomized, multicenter clinical trial of 440 patients designed to determine the efficacy and safety of andexanet compared to usual care in patients presenting with acute intracranial hemorrhage.

Study Type

Interventional - Drug

Study Design

Prospective, randomized, open-label, multicenter clinical trial

NO. of Countries

10

NO. of Sites

100

NO. of Participants

440

Study Period

2019-2022

Sponsor

Portola Pharmaceuticals

Portola Pharmaceuticals, Inc.

Back To Top